Kathryn Lancaster to Mass Screening
This is a "connection" page, showing publications Kathryn Lancaster has written about Mass Screening.
Connection Strength
1.142
-
Chen JS, Matoga M, Pence BW, Powers KA, Maierhofer CN, Jere E, Massa C, Khan S, Rutstein SE, Phiri S, Hosseinipour MC, Cohen MS, Hoffman IF, Miller WC, Lancaster KE. A randomized controlled trial evaluating combination detection of HIV in Malawian sexually transmitted infections clinics. J Int AIDS Soc. 2021 Apr; 24(4):e25701.
Score: 0.636
-
Lancaster KE, Stockton M, Remch M, Wester CW, Nash D, Brazier E, Adedimeji A, Finlayson R, Freeman A, Hogan B, Kasozi C, Kwobah EK, Kulzer JL, Merati T, Tine J, Poda A, Succi R, Twizere C, Tlali M, Groote PV, Edelman EJ, Parcesepe AM. Availability of substance use screening and treatment within HIV clinical sites across seven geographic regions within the IeDEA consortium. Int J Drug Policy. 2024 Feb; 124:104309.
Score: 0.193
-
Hood RB, Turner AN, Huber-Krum S, Lancaster KE, Mwapasa V, Poindexter T, Nampandeni P, Esber A, Norris AH. For Human Papillomavirus Self-Sampling, Stated Willingness Does Not Correspond With Subsequent Uptake by Rural Malawian Women. Sex Transm Dis. 2020 Apr; 47(4):275-279.
Score: 0.148
-
Toussova OV, Kozlov AP, Verevochkin SV, Lancaster KE, Shaboltas AV, Masharsky A, Dukhovlinova E, Miller WC, Hoffman IF. A Cohort Approach to Real-Time Detection of Acute HIV Infections Among People Who Inject Drugs in St. Petersburg, Russia. AIDS Res Hum Retroviruses. 2018 Mar; 34(3):261-268.
Score: 0.127
-
Parcesepe AM, Lancaster K, Edelman EJ, DeBoni R, Ross J, Atwoli L, Tlali M, Althoff K, Tine J, Duda SN, Wester CW, Nash D. Substance use service availability in HIV treatment programs: Data from the global IeDEA consortium, 2014-2015 and 2017. PLoS One. 2020; 15(8):e0237772.
Score: 0.038